Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

• Main Authors: Dipti Talaulikar, Ranjana H. Advani, Andrew R. Branagan, Christian Buske, Meletios A. Dimopoulos, Shirley D'Sa, Maria J. Kersten, Veronique Leblond, Monique C. Minnema, Roger G. Owen, Maria Lia Palomba, Alessandra Tedeschi, Judith Trotman, Marzia Varettoni, Josephine M. Vos, Steven P. Treon, Efstathios Kastritis, Jorge J. Castillo
• Format: Article
• Language: English
• Published: Wolters Kluwer 2020-08-01
• Series: HemaSphere
• Online Access: http://journals.lww.com/10.1097/HS9.0000000000000433

Abstract. In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.